Skip to main content
Article thumbnail
Location of Repository

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

By Jeffrey A Johnson, Jin-Fen Li, Xierong Wei, Jonathan Lipscomb, David Irlbeck, Charles Craig, Amanda Smith, Diane E Bennett, Michael Monsour, Paul Sandstrom, E. Randall Lanier and Walid Heneine

Abstract

Using real-time PCR to detect HIV resistance mutations present at low levels, Jeffrey Johnson and colleagues investigate prevalence and clinical implications of minority transmitted mutations

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2488194
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). The epidemiology of antiretroviral drug resistance among drugnaı ¨ve HIV-1 infected persons in 10 U.S.
    2. (2002). Time trends in primary HIV-1 drug resistance among recently infected persons.
    3. (2006). A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program.
    4. (2002). Antiretroviral-drug resistance among patients recently infected with HIV.
    5. (2006). Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance.
    6. (2005). Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
    7. (2004). Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.
    8. (2004). Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.
    9. (2002). Persistance and fitness of multidrug-resistant of human immunodeficiency virus type 1 acquired in primary HIV infection.
    10. (2006). HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    11. (2003). Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.
    12. (2004). Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy [Abstract
    13. (2004). et al.Co-Investigators of the Quebec Primary Infection Study
    14. (2001). Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naı ¨ve persons.
    15. Garcı ´a-Lerma JG (2007) The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
    16. (1998). Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.
    17. (2004). Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    18. (2004). Lowfrequency NNRTI-resistant variants contribute to failure of efavirenzcontaining regimens
    19. (2007). Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations.
    20. (2005). Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    21. (2006). Categorization of HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method.
    22. (2005). Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naı ¨ve HIV-infected adults.
    23. (2004). Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naı ¨ve HIV-infected adults.
    24. (2004). Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    25. (2007). HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
    26. (2004). Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes.
    27. (2006). Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.
    28. (2005). HIV drug resistance acquired through superinfection.
    29. (2007). Dynamics of virus replication and antiviral drug resistance in a new RT-SHIV macaque model of antiviral therapy.
    30. (2007). Prevalence of low abundant drug-resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral-naı ¨ve patients and the impact on on virologic outcomes.
    31. (2008). Presence of minor populations of Y181C mutants detected by allelespecific PCR and risk of efavirenz failure in treatment-naı ¨ve patients:
    32. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.